ليتروزول تيڤع

Land: Israel

Språk: arabisk

Kilde: Ministry of Health

Aktiv ingrediens:

LETROZOLE 2.5 MG

Tilgjengelig fra:

TEVA PHARMACEUTICAL INDUST.LTD

ATC-kode:

L02BG04

Legemiddelform:

TABLETS

Administreringsrute:

PER OS

Produsert av:

TEVA PHARMACEUTICAL INDUSTRIES LTD

Terapeutisk gruppe:

LETROZOLE

Indikasjoner:

Letrozole teva tablets is indicated for first-line treatment in postmenopausal women with hormone receptor positive or in whom hormone receptor status cannot be determined, locally advanced or metastatic breast cancer: Letrozole teva is also indicated for the treatment of advanced breast cancer in postmenopausal women with disease progression following antiestrogen therapy. Extended adjuvant treatment of early breast cancer in post menopausal women who have received prior standard adjuvant tamoxifen therapy. Adjuvant treatment of postmenopausal women with hormone receptor positive early breast cancer.

Autorisasjon dato:

2010-01-01